Please use this identifier to cite or link to this item: http://bdtd.uftm.edu.br/handle/tede/863
Full metadata record
DC FieldValueLanguage
dc.creatorLIMA, Cid Almeida de-
dc.creator.Latteshttp://lattes.cnpq.br/9717640994897581por
dc.contributor.advisor1NOMELINI, Rosekeila Simões-
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/0564643325267326por
dc.contributor.advisor-co1MURTA, Eddie Fernando Cândido-
dc.contributor.advisor-co1Latteshttp://lattes.cnpq.br/5724192420139830por
dc.date.accessioned2019-09-13T17:50:01Z-
dc.date.issued2019-06-14-
dc.identifier.citationLIMA, Cid Almeida de. Avaliação de linfócitos no estroma peritumoral de neoplasias epitelais de ovário. 2019. 113f . Tese (Doutorado em Ciências da Saúde) - Programa de Pós-Graduação em Ciências da Saúde, Universidade Federal do Triângulo Mineiro, Uberaba, 2019 .por
dc.description.resumoOBJETIVOS: O câncer de ovário é uma doença heterogênea, onde a inflamação crônica é um dos mecanismos centrais de sua patogênese. A localização, subtipo e densidade dos Linfócitos que Infiltram Tumores (TILs) são os principais determinantes desse valor prognóstico. Os objetivos do estudo foram avaliar a expressão de CD3, CD4, CD8 e CD20 no estroma peritumoral de neoplasias epiteliais ovarianas primárias benignas e malignas e relacioná-las a fatores prognósticos (níveis séricos de marcadores tumorais, tipo histológico, comprometimento de linfonodos, resposta à quimioterapia, sobrevida livre de doença, estadiamento e grau de diferenciação do tumor) no câncer de ovário. PACIENTES E MÉTODOS: Foram avaliados 77 pacientes atendidas no Ambulatório de Massa Pélvica do Departamento de Ginecologia e Obstetrícia/Instituto de Pesquisa em Oncologia (IPON) da Universidade Federal do Triângulo Mineiro. Foi realizado estudo imuno-histoquímico para imunomarcadores (CD3, CD4, CD8 e CD20). A avaliação dos fatores prognósticos foi realizada pelo teste exato de Fisher. O nível de significância foi menor que 0,05. RESULTADOS: Maior expressão de CD3 foi encontrada no estroma de neoplasias malignas primárias de ovário quando comparado ao grupo de neoplasias benignas, e maior expressão de células CD4 no estroma de neoplasias benignas em comparação ao câncer de ovário. Ao correlacionar a expressão de imunomarcadores com fatores prognósticos, houve maior expressão de células CD8 nas neoplasias malignas estromais ovarianas, com subtipo molecular II do modelo de carcinogênese ovariana epitelial, em relação ao tipo I. Na avaliação das metástases linfonodais, a ausência de marcação imunológica de células CD20 foi associada à ausência de metástases linfonodais. CONCLUSÃO: O sistema imune desempenha um papel multifacetado e pode, em diferentes contextos, promover ou inibir o crescimento do tumor. O aumento da imunocoloração de CD3 é encontrado em neoplasmas malignas, enquanto o aumento da imunomarcação de CD4 está associado a neoplasias ovarianas benignas. A imunomarcação de CD8 foi maior nos tumores do tipo II, enquanto a ausência de imunomarcação de CD20 foi associada à ausência de metástases linfonodais.por
dc.description.abstractOBJECTIVES: Ovarian cancer is a heterogeneous disease, where chronic inflammation is one of the central mechanisms of its pathogenesis. The location, subtype and density of Lymphocyte Tumor Infiltrators (TILs) are the main determinants of this prognostic value. The objectives of the study were to evaluate the expression of CD3, CD4, CD8 and CD20 in the peritumoral stroma of benign and malignant primary ovarian epithelial neoplasms and to relate them to prognostic factors (serum levels of tumor markers, histological type, lymph node involvement, response to chemotherapy, disease-free survival, staging, and degree of tumor differentiation) in ovarian cancer. PATIENTS AND METHODS: We evaluated 77 patients treated at the Pelvic Mass Outpatient Clinic of the Department of Gynecology and Obstetrics / Institute of Oncology Research (IPON) of the Federal University of Triângulo Mineiro. Immunohistochemistry study for cytokines (CD3, CD4, CD8 and CD20) was performed. The evaluation of prognostic factors was performed using the Fisher's exact test. The significancelevelwas less than 0.05. RESULTS: A higher CD3 expression was found in the stroma of primary ovarian malignancies when compared to the group of benign neoplasms, and greater expression of CD4 cells in the stroma of benign neoplasms compared to ovarian cancer. By correlating the expression of cytokines with prognostic factors, there was a greater expression of CD8 cells in the stromal ovarian malignancies with molecular subtype II of the model of epithelial ovarian carcinogenesis compared to type I. In the evaluation of lymph node metastases, the absence of immuno-labeling of CD20 cells was associated with the absence of lymph node metastases. CONCLUSION: The immune system plays a multifaceted role and can, in different contexts, promote or inhibit tumor growth. Increased immunostaining of CD3 is found in malignant neoplasms, while increased CD4 immunostaining is associated with benign ovarian neoplasms. CD8 immunostaining was greater in type II tumors, while the absence of CD20 immunostaining was associated with the absence of lymph node metastases.eng
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológicopor
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de Minas Geraispor
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superiorpor
dc.formatapplication/pdf*
dc.thumbnail.urlhttp://bdtd.uftm.edu.br/retrieve/5764/Tese%20Cid%20A%20de%20Lima.pdf.jpg*
dc.languageporpor
dc.publisherUniversidade Federal do Triângulo Mineiropor
dc.publisher.departmentInstituto de Ciências da Saúde - ICS::Programa de Pós-Graduação em Ciências da Saúdepor
dc.publisher.countryBrasilpor
dc.publisher.initialsUFTMpor
dc.publisher.programPrograma de Pós-Graduação em Ciências da Saúdepor
dc.relation.referencesALQASEMI, U.; KUMAVOR, P.; AGUIRRE, A.; ZHU, Q. Recognition algorithm for assisting ovarian cancer diagnosis from coregistered ultrasound and photoacoustic images: ex vivo study. Journal of Biomedical Optics. v.17, n.12, p.1-10, 2012. AMIRA, G.; MORSI, A.; FAYEK, I.S.; MANSOUR, O.; NADER, H. Hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in recurrent platinum-sensitive ovarian cancer NCI case control study. Asian Pacific Journal of Cancer Prevention. v. 20, n.2, p.621-627, 2019. AMERICAN CANCER SOCIETY. Cancer Facts & Figures 2019. Special Section: Ovarian Cancer. Atlanta, GA, 2019. Disponível em: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/ annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf>.p:4;20. Acesso em: 28 de fevereiro de 2019. ARANGO, H.G. Bioestatística teórica e computacional. Rio de Janeiro: Guanabara Koogan, 2001. p. 93-113. ASHER, V.; LEE, J.; INNAMAA, A. et al. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clinical & Translational Oncology. v.13, n.7, p.499-503, 2011. ASHRAFGANJOEI, T.; MOHAMADIANAMIRI, M.; FARZANEH, F. et al. Investigating preoperative hematologic markers for prediction of ovarian cancer surgical outcome. Asian Pacific Journal of Cancer Prevention. v.17, n.3, p.1445-1448, 2016. BAERT, T.; TIMMERMAN, D.; VERGOTE, I.; COOSEMANS, A. Immunological parameters as a new lead in the diagnosis of ovarian cancer. Facts, Views & Vision in ObGyn. v.7, n.1, p.67-72, 2015. BELISLE, J.A.; HORIBATA, S.; JENNIFER, G.A. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Molecular cancer. v.9, n.118, p.1-14, 2010. BELOV, L.; de la VEJA, O.; dos REMEDIOS, C.G. et al. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Research. v.61, n.11, p.4483-89, 2001. BOUAZIZ, J.D.; YANABA, K, VENTURI G.M. et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proceedings of the National Academy of Sciences of the USA. v.104, n.52, p.20878-20883, 2007. BOUGHERARA, H.; MANSUET-LUPO, A.; ALIFANO, M. et al. Real-time imaging of resident T cells in human lung and ovarian carcinomas reveals how different tumor microenvironments control T lymphocyte migration. Frontiers in Immunology. v.6, p.500, 2015. BOULTON, S.J.Cellular functions of the BRCA tumour-suppressor proteins. Biochemical Society Transactions. v.34, n.5, p.633-645, 2006. BREMNES, R.M.; DØNNEM, T.; AL-SAAD, S. et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. Journal of Thoracic Oncology. v.1, p.209-217, 2011. CHERCHI, P.L.; CAPOBIANCO, G.; AMBROSINI, G. et al. Intracystic evaluation of tumor markers in benign and malignant ovarian pathology. European journal of gynaecological oncology. v.23, n.2, p.163-165, 2002. CHOBANIAN, N.; DIETRICH, C.S. Ovarian cancer. Surgical Clinics North America. v.88, n.2, 285-299, 2008. CLARKE, B.; TINKER, A.V.; LEE, C.H. et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology. v.22, n.3, p.393-402, 2009. CLARKE-PEARSON, D.L. Clinical practice. Screening for ovarian cancer. New England Journal of Medicine. v.361, n.2, p.170-177, 2009. COOSEMANS, A.; BAERT, T.; VERGOTE, I. A view on dendritic cell immunotherapy in ovarian cancer: how far have we come? Facts, Views & Vision in ObGyn. v.7, n.1, p.73-78, 2015. COUGHLIN, C.M.; VANCE, B.A.; GRUPP, S.A.; VONDERHEIDE, R.H. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood. v.103, n.6, p.2046-54, 2004. CUBILLOS-RUIZ, J.R.; RUTKOWSKI, M.; CONEJO-GARCIA, J.R. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle. v.9, n.2, p.260-268, 2010. deVISSER K.E.; KORETS, L.V.; COUSSENS, L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. v.7, n.5, p.411-423, 2005. DIAZ-CUETO, L.; ARECHAVALETA-VELASCO, F.; DIAZ-ARIZAGA, A. et al. PKC signaling is involved in the regulation of progranulin (acrogranin/PC-cell-derived growth factor/granulin-epithelin precursor) protein expression in human ovarian cancer cell lines. International Journal of Gynecological Cancer. v.22, n.6, p.945-950, 2012. DOTLIĆ, J.; TERZIĆ, M.; LIKIĆ, I. et al. Evaluation of adnexal masses: correlation between clinical, ultrasound and histopathological findings. Vojnosanitetski Pregled. v.68, n. 10, p.861-866, 2011. EDGELL, T.; MARTIN-ROUSSETY, G.; BARKER, G. et al. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. Journal of Cancer Research and Clinical Oncology. v.136, n.7, p.1079-1088, 2010. ELLMARK P.; WOOLFSON, A.; BELOV, L.; CHRISTOPHERSON, R.I. The Applicability of a Cluster of Differentiation Monoclonal Antibody Microarray to the Diagnosis of Human Disease. Methods in Molecular Biology. v.439, p.199-209, 2008. GADDUCCI, A.; COSIO, S.; CONTE, P.F.; GENAZZANI, A.R. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after firstline chemotherapy: a review of the literature. Critical Reviews in Oncology/Hematology. v.55, n.2, p.153-166, 2005. GADDUCCI, A.; COSIO, S.; ZOLA, P. et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. International Journal of Gynecological Cancer. v.17, n.1, p.21-31, 2007. GLOBOCAN 2019 - International Agency for Research on Cancer (IARC)/Cancer Registries International Agency for Research on Cancer, Worl Health Organization. Lyon, France. v.1 p.2. Disponível em: <http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf> Acesso em: 14 de março de 2019. HAMANISHI, J.; MANDAI, M.; ABIKO, K. et al. The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clinical Immunology. v.141, n.3, p.338-347, 2011. HAN, L.Y.; FLETCHER, M.S.; URBAUER, D.L. et al. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independente prognostic markers in ovarian carcinoma. Clinical Cancer Research. v.14, n.11, p.3372-3379, 2008. HORIUCHI, A.; ITOH, K.; SHIMIZU, M. et al. Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecologic Oncology. v.88, n.3, p.309-317, 2003. IGLESIA, M.D.; VINCENT, B.G.; PARKER, J.S. et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clinical Cancer Research. v.20, n.14, p.3818-29, 2014. INSTITUTO NACIONAL DO CÂNCER - INCA, Estimativa 2018-2019: Incidência de Câncer no Brasil/Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. p. 52,53,58, Rio de Janeiro, RJ, 2019. Disponível em: < http://www.inca.gov.br/estimativa/2018/estimativa-2018.pdf>. JAMMAL, M.P.; LIMA, C.A.; MURTA, E.F.C.; NOMELINI, R.S. Is Ovarian Cancer Prevention Currently Still a recommendation of Our Grandparents? Revista Brasileira de Ginecologia e Obstetrícia. v.39, n.12, p.676-685, 2017. JARNICKI, A.G.; LYSAGHT, J.; TODRYK, S.; MILLS, K.H.; Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. Journal of Immunology. v.177, n.2, p.896-904, 2006. JIA, L.; REN, J.M.; WANG, Y.Y. et al. Inhibitory role of prohibitin in human ovarian epithelial cancer. International Journal of Clinical and Experimental Pathology. v.7, n.5, p.2247-55, 2014. KALLURI, R.; ZEISBERG, M. Fibroblasts in cancer. Nature Reviews. Cancer. v.6, n.5, p.392-401, 2006. KINDELBERGER, D.W.; LEE, Y.; MIRON, A. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. American Journal of Surgical Pathology. v.31, n.2, p.161-169, 2007. KNUTSON, K.L.; CURIEL, T.J.; SALAZAR, L.; DISIS, M.L. Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematology/oncology Clinics of North America. v.17, n.4, p.1051-1073, 2003. KROEGER, D.R.; MILNE, K.; NELSON, B.H. Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer. Clinical Cancer Research. v.22, n.12, p.3005-3015, 2016. KURMAN, R.J.; SHIH, IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer. Shifting the paradigm. Human Pathology. v.42, n.7, p.918-931, 2011. KURMAN, R.J.; SHIH, IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. The American Journal of Pathology. v.2016186, n.4, p.733-47, 2016. KURMAN, R.J.; SHIH, IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. The American Journal of Surgical Pathology. v.34, n.3, p.433-443, 2010. LABIDI-GALY, S.I.; PAPP, E.; HALLBERG, D. et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications. v.8, n.1, p.1093, 2017. LAVOUÉ, V.; THÉDREZ, A.; LEVÊQUE, J. et al. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. Journal of Translational Medicine. v.11, n.147, p.1-12, 2013. LE PAGE, C.; MARINEAU, A.; BONZA, P.K. et al. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS One. v.7, n.6, p.e38541, 2012. LEFFERS, N.; GOODEN, M.J.; de JONG, R.A. et al. Prognostic significance of tumorinfiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunology and Immunotherapy. v.58, n.3, p.449-459, 2009. LEHNHARDT, A.; MENGEL, M.; PAPE, L.; EHRICH, J.H.; OFFNER, G.; STREHLAU, J. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab. American Journal of Transplantation. v.6, n.4, p.847-851, 2006. LEWIS K.E.; LU K.H.; KLIMCZAK A.M.; MOK S.C. Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision. Cancers (Basel). v.10, n.2, p.1-11, 2018. LIMA C.A.; JAMMAL, M.P.; MARTINS-FILHO, A. et al. Stromal Growth Differentiation Factor 15 and Its Association with Ovarian Cancer. Gynecologic and Obstetric Investigation. v.83, n.1, p.35-39, 2018. LI, J.; WANG, J.; CHEN, R.; BAI, Y.; LU, X. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget. v.8, n.9, p.15621-15631, 2017. LIU, A.Y. Differential expression of cell surface molecules in prostate cancer cells. Cancer Research. v.60, n.13, p.3429-34, 2000. LIU, A.Y.; TRUE, L.D. Characterization of prostate cell types by CD cell surface molecules. The American Journal of Pathology. v.160, n.1, p.37-43, 2003. LUKESOVA, S.; VROBLOVA, V.; TOSNER, J. et al. Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. Contemporary Oncology (Poznań, Poland). v.19, n.4, p. 290-299, 2015. LUNDGREN, S.; BERNTSSON, J.; NODIN, B. et al. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. Journal of Ovarian Research. v.9, n.21, s.p. 2016. MAHMOUD, S.M.; LEE, A.H.; PAISH, E.C. et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Research and Treatment. v.132, n.2, p.545-553, 2012. MATTOS, L.L.; MACHADO, L.N.; SUGIYAMA, M.M. et al. Tecnologia aplicada na detecção de marcadores tumorais. Arquivos Médicos do ABC. v.30, n.1, p.19-25, 2005. MAVADDAT N.; PEOCK S.; FROST D. et al. EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute. v.105, n.11, p.812-22, 2013. MILNE, K.; KÖBEL, M.; KALLOGER, S.E. et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. v.4, n.7, p.e6412, 2009. Erratum in: PLoS One. v.8, n.7, 2009. MILLIKEN, D.; SCOTTON, C.; RAJU, S.et al. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clinical Cancer Research. v.8, n.4, p.1108-114, 2002. MIRONOV, S.; AKIN, O.; PANDIT-TASKAR, N.; HANN, L.E. Ovarian Cancer. Radiologic Clinics of North America. v.45, n.1, p.149-166, 2007. MOK, S.C.; KWONG, J.; WELCH, W.R. et al. Etiology and pathogenesis of epithelial ovarian cancer. Disease Markers; v.23, n.5-6, p.367-376, 2007. MONTFORT, A.; PEARCE, O.; MANIATI, E.; et al. A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases. Clinical Cancer Research. v.23, n.1, p.250-262, 2017. MOORE, R.G.; MCMEEKIN, D.S.; BROWN, A.K. et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology. v.112, n.1, p.40-46, 2009. MOR, G.; VISINTIN, I.; LAI, Y. et al. Serum protein markers for early detection of ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. v.102, n.21, p.7677-7682, 2005. MORETTA, L.; BOTTINO, C.; PENDE, D. et al. Human natural killer cells: their origin, receptors and function. European journal of immunology. v.32, n.5, p.1205-1211, 2002. MURTA, E.F.; da SILVA, C.S.; GOMES, R.A. et al. Ultrasonographic criteria and tumor marker assay are good procedures for the diagnosis of ovarian neoplasia in preselected outpatients. European journal of gynaecological oncology.v.25, n.6, p.707-712, 2004. MURTA, E.F.; NOMELINI, R.S. Early diagnosis and predictors of malignancy of adnexal masses. Current opinion in obstetrics & gynecology. v.18, n.1, p.14-19, 2006. MURTA, E.F.C.; ANDRADE, J.M.; BIGHETTI, S. Aspectos epidemiológicos do câncer de ovário. Jornal Brasileiro de Ginecologia. v.105, n.6, p.269-274, 1995. NIELSEN, J.S.; SAHOTA, R.A.; MILNE, K. et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clinical Cancer Research. v.18, n.12, p.3281-3292, 2012. NUNES, N.; AMBLER, G.; FOO, X. et al. Use of IOTA simple rules for diagnosis of ovarian cancer: meta-analysis. Ultrasound in Obstetrics and Gynecology. v.44, n.5, p.503-514, 2014. PEREIRA, P.N.; SARIAN, L.O.; YOSHIDA, A.; et al. Accuracy of the ADNEX MR scoring system based on a simplified MRI protocol for the assessment of adnexal masses. Diagnostic and Interventional Radiology. v.24, n.2, p.63-71, 2018. PINTO, M.P.; BALMACEDA, C.; BRAVO, M.L. et al. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. Gynecologic Oncology. v.151, n.1, p.10-17, 2018. PRZYBYCIN, C.G.; KURMAN, R.J.; RONNETT, B.M. et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? American Journal of Surgical Pathology. v.34, n. 10, p.1407-1416, 2010. REBBECK, T.R.; LYNCH, H.T.; NEUHAUSEN, S.L. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England Journal of Medicine v.346, n.21, p.1616-1622, 2002. READE C.J.; MCVEY R.M.; TONE A.A. et al. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. Journal of obstetrics and gynaecology Canada. v.36, n.2, p.133-140, 2014. REIS, F.J.C. Rastreamento e diagnóstico das neoplasias de ovário - papel dos marcadores tumorais. Revista Brasileira de Ginecologia e Obstetrícia. v.27, n.4, p.222-227, 2005. RISCH, H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. Journal of the National Cancer Institute.v.90, n.23, p.1774-1786, 1998. RISCH, H.A.; WEISS, N.S.; LYON, J.L. et al. Events of reproductive life and the incidence of epithelial ovarian cancer. American Journal of Epidemiology. v.117, n.2, p.128-139, 1983. RÅDESTAD, E.; KLYNNING, C.; STIKVOORT, A. et al. Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. Oncoimmunology. v.8, n.2, p.e1535730, 2018. RODRÍGUEZ-PINTO D. B cells as antigen presenting cells. Cellular Immunology. v.238, n.2, p.67-75, 2005. ROSEN, E.M.; FAN, S.; PESTELL R.G.; GOLDBERG, I.D. BRCA1 gene in breast cancer. Journal of Cellular Physiology. v.196, n.1, p.19-41, 2003. RUDENSKY, A.Y. Regulatory T cells and Foxp3. Immunological Reviews. v.241, n.1, p.260-268, 2011. RYNER, L.; GUAN, Y.; FIRESTEIN, R. et al. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. Clinical Cancer Research. v.21, n.13, p.2941-2951, 2015. SATO, E.; OLSON, S.H.; AHN, J. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. v.102, n.51, p.18538-43, 2005. SCHILDKRAUT, J.M.; THOMPSON, W.D.; Familial ovarian cancer: a population based case control study. American Journal of Epidemiology. v.128, n.3, p.456-466, 1988. SCHMELER, K.M.; SUN C. C.; BODURKA D. C. et al. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstetrics & Gynecology. v.108, n.3, p.515-520, 2006. SENTURK, E.; COHEN, S.; DOTTINO, P.R.; MARTIGNETTI, J.A. A critical re-appraisal of BRCA1 methylation studies in ovarian cancer. Gynecologic Oncology. v.119, n.2, p.376-383, 2010. SIMAGA, S.; OSMAK, M.; BABIC, D. et al. Quantitative biochemical analysis of lactate dehydrogenase in human ovarian tissues: correlation with tumor grade. International Journal of Gynecological Cancer. v.15, n.3, p.438-444, 2005. STONE, B.; SCHUMMER, M.; PALEY, P.J. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. International Journal of Cancer. v.104, n.1, p.73-84, 2003. TABASSUM, D.P.; POLYAK, K. Tumorigenesis: it takes a village. Nature Reviews. Cancer. v.15, n.8, p.473-483, 2015. TAVARES-MURTA, B.M.; CUNHA, F.Q.; MIRANDA, R. et al. Differential tumor microenvironment in human ovarian cystic tumors. Tumori. v.90, n.5, p.491-497, 2004. TAVASSOLI, F. A.; DEVILEE, P. (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon 2003. TERADA, K.Y.; AHN, H.J.; KESSEL, B. Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. Journal of Gynecologic Oncology. v.27, n.3, p.e25, 2016. VALMORI, D.; AYYOUB, M. CD4(+) T helper cell responses to NY-ESO-1 tumor antigen in ovarian cancer resist perversion into immunosuppressive Tregs. Oncoimmunology. v.4, n.12, p.e946370, 2014. VAN CALSTER, B.; VAN HOORDE, K.; VALENTIN, L. et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. British Medical Journal. v.349, n.G5920, p.1-14, 2014. VAN NIEKERK, C.C.; RAMAEKERS, F.C.; HANSELAAR, A.G. et al. Changes in expression of differentiation markers between normal ovarian cells and derived tumors. The American journal of pathology. v.142, n.1, p.157-177, 1993. VISVANATHAN, K.; SHAW, P.; MAY, B.J. et al. Fallopian tube lesions in women at high risk for ovarian cancer: a multicenter study. Cancer Prev Res (Phila). Cancer Prevention Research. v.11, n.11, p.697-706. 2018. VRABIE, C.D.; PETRESCU, A.; WALLER, M.; DINA, I. Clinical factors and biomarkers in ovarian tumors development. Romanian Journal of Morphology and Embryology. v.49, n.3, p.327-338, 2008. WANG, Q.; LOU, W.; DI, W.; WU, X. Prognostic value of tumor PD-L1 expression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer. International Immunopharmacology. v.52, p.7-14, 2017. XU, Y.; HOU, Y.; LIU, T.; LOU, G. Overexpression and clinical significance of IBP in epithelial ovarian carcinoma. Oncology letters. v.15, n.5, p.6604-6610, 2018. WANG, R.F. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Human Immunology. v.69, n.11, p.811-814, 2008. YANG, L.; WANG, S.; ZHANG, Q. et al. Clinical significance of the immune microenvironment in ovarian cancer patients. Molecular Omics. v.14, n.5, p.341-351, 2018. YILDIRIM, N.; AKMAN, L.; ACAR, K. et al. Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer? European Journal of Obstetrics, Gynecology, and Reproductive Biology. v.215, p.55-61, 2017. ZHANG, F.; ZHANG, Z.L. The Diagnostic Value of Transvaginal Sonograph (TVS), Color Doppler, and Serum Tumor Marker CA125, CEA, and AFP in Ovarian Cancer. Cell Biochemistry and Biophysics. v.72, n.2, p.353-357, 2015. ZHANG, J.; LI, Y.L.; ZHOU, C.Y. et al. Expression of octamer-4 in serous and mucinous ovarian carcinoma. Journal of Clinical Pathology. v.63, n.10, p.879-883, 2010. ZHANG, L.; CONEJO-GARCIA, J.R.; KATSAROS, D. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England journal of medicine. v.348, n.3, 203-213, 2003. ZHANG, S.; KE, X.; ZENG, S. et al. Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment. Cellular & Molecular Immunology. v.12, n.5, p.580-591, 2015b. ZEPPERNICK, F.; MEINHOLD-HEERLEIN, I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal câncer. Archives of gynecology and obstetrics. v. 290, p. 839-842, 2014. ZOLA, H.; SWART, B.; NICHOLSON, I. et al. CD molecules 2005: human cell differentiation molecules. Blood. v.106, n.9, p.3123-26, 2005.por
dc.rightsAcesso Abertopor
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.subjectCâncer de ovário.por
dc.subjectLinfócitos tumor infiltrantes.por
dc.subjectFatores prognósticos.por
dc.subjectOvarian cancer.eng
dc.subjectTumor-infiltrating lymphocytes.eng
dc.subjectPrognostic factors.eng
dc.subject.cnpqCancerologiapor
dc.titleAvaliação de linfócitos no estroma peritumoral de neoplasias epitelais de ováriopor
dc.typeTesepor
Appears in Collections:Programa de Pós-Graduação em Ciências da Saúde

Files in This Item:
File Description SizeFormat 
Tese Cid A de Lima.pdfTese Cid A de Lima4,07 MBAdobe PDFThumbnail

Download/Open Preview


This item is licensed under a Creative Commons License Creative Commons